増殖性硝子体網膜症（PVR）治療薬の世界市場（～2026年）

• 英文タイトル：Global Proliferative Vitreoretinopathy (PVR) Therapeutics Market Insights and Forecast to 2026

• レポートコード：MRC2-11QY14418 • 出版社/出版日：QYResearch / 2020年11月30日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、119ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬

• 販売価格（消費税別）

Single User	￥577,200 (USD3,900)	▷ お問い合わせ
Multi User	￥865,800 (USD5,850)	▷ お問い合わせ
Enterprise License	￥1,154,400 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

当調査資料は増殖性硝子体網膜症（PVR）治療薬のグローバル市場について調査・分析したレポートです。種類別（PRM-167、XOMA-089、その他）市場規模、用途別（病院、クリニック、ASC、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別増殖性硝子体網膜症（PVR）治療薬の競争状況、市場シェア ・世界の増殖性硝子体網膜症（PVR）治療薬市場：種類別市場規模 2015年-2020年（PRM-167、XOMA-089、その他） ・世界の増殖性硝子体網膜症（PVR）治療薬市場：種類別市場規模予測 2021年-2026年（PRM-167、XOMA-089、その他） ・世界の増殖性硝子体網膜症（PVR）治療薬市場：用途別市場規模 2015年-2020年（病院、クリニック、ASC、その他） ・世界の増殖性硝子体網膜症（PVR）治療薬市場：用途別市場規模予測 2021年-2026年（病院、クリニック、ASC、その他） ・北米の増殖性硝子体網膜症（PVR）治療薬市場分析：米国、カナダ ・ヨーロッパの増殖性硝子体網膜症（PVR）治療薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの増殖性硝子体網膜症（PVR）治療薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の増殖性硝子体網膜症（PVR）治療薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの増殖性硝子体網膜症（PVR）治療薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Novartis AG、Promedior Inc、RXi Pharmaceuticals Corp ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論

Market Analysis and Insights: Global Proliferative Vitreoretinopathy (PVR) Therapeutics Market
The global Proliferative Vitreoretinopathy (PVR) Therapeutics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.

Global Proliferative Vitreoretinopathy (PVR) Therapeutics Scope and Market Size
Proliferative Vitreoretinopathy (PVR) Therapeutics market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Proliferative Vitreoretinopathy (PVR) Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.

Segment by Type, the Proliferative Vitreoretinopathy (PVR) Therapeutics market is segmented into
PRM-167
XOMA-089
Others

Segment by Application, the Proliferative Vitreoretinopathy (PVR) Therapeutics market is segmented into
Hospital
Clinic
ASCs
Others

Regional and Country-level Analysis
The Proliferative Vitreoretinopathy (PVR) Therapeutics market is analysed and market size information is provided by regions (countries).
The key regions covered in the Proliferative Vitreoretinopathy (PVR) Therapeutics market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Proliferative Vitreoretinopathy (PVR) Therapeutics Market Share Analysis
Proliferative Vitreoretinopathy (PVR) Therapeutics market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Proliferative Vitreoretinopathy (PVR) Therapeutics business, the date to enter into the Proliferative Vitreoretinopathy (PVR) Therapeutics market, Proliferative Vitreoretinopathy (PVR) Therapeutics product introduction, recent developments, etc.

The major vendors covered:
Novartis AG
Promedior Inc
RXi Pharmaceuticals Corp
…

レポート目次

---

1 Study Coverage
1.1 Proliferative Vitreoretinopathy (PVR) Therapeutics Product Introduction
1.2 Market Segments
1.3 Key Proliferative Vitreoretinopathy (PVR) Therapeutics Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size Growth Rate by Type
1.4.2 PRM-167
1.4.3 XOMA-089
1.4.4 Others
1.5 Market by Application
1.5.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size Growth Rate by Application
1.5.2 Hospital
1.5.3 Clinic
1.5.4 ASCs
1.5.5 Others
1.6 Study Objectives
1.7 Years Considered

2 Executive Summary
2.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size, Estimates and Forecasts
2.1.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue 2015-2026
2.1.2 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales 2015-2026
2.2 Global Proliferative Vitreoretinopathy (PVR) Therapeutics, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Retrospective Market Scenario in Revenue by Region: 2015-2020

3 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Competitor Landscape by Players
3.1 Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Manufacturers
3.1.1 Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Manufacturers (2015-2020)
3.1.2 Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Manufacturers (2015-2020)
3.2 Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Manufacturers
3.2.1 Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Manufacturers (2015-2020)
3.2.2 Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue in 2019
3.2.5 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Proliferative Vitreoretinopathy (PVR) Therapeutics Price by Manufacturers
3.4 Proliferative Vitreoretinopathy (PVR) Therapeutics Manufacturing Base Distribution, Product Types
3.4.1 Proliferative Vitreoretinopathy (PVR) Therapeutics Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Proliferative Vitreoretinopathy (PVR) Therapeutics Product Type
3.4.3 Date of International Manufacturers Enter into Proliferative Vitreoretinopathy (PVR) Therapeutics Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)
4.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size by Type (2015-2020)
4.1.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Type (2015-2020)
4.1.2 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Type (2015-2020)
4.1.3 Proliferative Vitreoretinopathy (PVR) Therapeutics Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size Forecast by Type (2021-2026)
4.2.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Forecast by Type (2021-2026)
4.2.2 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Forecast by Type (2021-2026)
4.2.3 Proliferative Vitreoretinopathy (PVR) Therapeutics Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

5 Market Size by Application (2015-2026)
5.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size by Application (2015-2020)
5.1.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Application (2015-2020)
5.1.2 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Application (2015-2020)
5.1.3 Proliferative Vitreoretinopathy (PVR) Therapeutics Price by Application (2015-2020)
5.2 Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size Forecast by Application (2021-2026)
5.2.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Forecast by Application (2021-2026)
5.2.2 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Forecast by Application (2021-2026)
5.2.3 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Price Forecast by Application (2021-2026)

6 North America
6.1 North America Proliferative Vitreoretinopathy (PVR) Therapeutics by Country
6.1.1 North America Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Country
6.1.2 North America Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Proliferative Vitreoretinopathy (PVR) Therapeutics Market Facts & Figures by Type
6.3 North America Proliferative Vitreoretinopathy (PVR) Therapeutics Market Facts & Figures by Application

7 Europe
7.1 Europe Proliferative Vitreoretinopathy (PVR) Therapeutics by Country
7.1.1 Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Country
7.1.2 Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Market Facts & Figures by Type
7.3 Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Market Facts & Figures by Application

8 Asia Pacific
8.1 Asia Pacific Proliferative Vitreoretinopathy (PVR) Therapeutics by Region
8.1.1 Asia Pacific Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Region
8.1.2 Asia Pacific Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Proliferative Vitreoretinopathy (PVR) Therapeutics Market Facts & Figures by Type
8.3 Asia Pacific Proliferative Vitreoretinopathy (PVR) Therapeutics Market Facts & Figures by Application

9 Latin America
9.1 Latin America Proliferative Vitreoretinopathy (PVR) Therapeutics by Country
9.1.1 Latin America Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Country
9.1.2 Latin America Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Proliferative Vitreoretinopathy (PVR) Therapeutics Market Facts & Figures by Type
9.3 Central & South America Proliferative Vitreoretinopathy (PVR) Therapeutics Market Facts & Figures by Application

10 Middle East and Africa
10.1 Middle East and Africa Proliferative Vitreoretinopathy (PVR) Therapeutics by Country
10.1.1 Middle East and Africa Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Country
10.1.2 Middle East and Africa Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Proliferative Vitreoretinopathy (PVR) Therapeutics Market Facts & Figures by Type
10.3 Middle East and Africa Proliferative Vitreoretinopathy (PVR) Therapeutics Market Facts & Figures by Application

11 Company Profiles
11.1 Novartis AG
11.1.1 Novartis AG Corporation Information
11.1.2 Novartis AG Description and Business Overview
11.1.3 Novartis AG Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Novartis AG Proliferative Vitreoretinopathy (PVR) Therapeutics Products Offered
11.1.5 Novartis AG Related Developments
11.2 Promedior Inc
11.2.1 Promedior Inc Corporation Information
11.2.2 Promedior Inc Description and Business Overview
11.2.3 Promedior Inc Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Promedior Inc Proliferative Vitreoretinopathy (PVR) Therapeutics Products Offered
11.2.5 Promedior Inc Related Developments
11.3 RXi Pharmaceuticals Corp
11.3.1 RXi Pharmaceuticals Corp Corporation Information
11.3.2 RXi Pharmaceuticals Corp Description and Business Overview
11.3.3 RXi Pharmaceuticals Corp Sales, Revenue and Gross Margin (2015-2020)
11.3.4 RXi Pharmaceuticals Corp Proliferative Vitreoretinopathy (PVR) Therapeutics Products Offered
11.3.5 RXi Pharmaceuticals Corp Related Developments
11.1 Novartis AG
11.1.1 Novartis AG Corporation Information
11.1.2 Novartis AG Description and Business Overview
11.1.3 Novartis AG Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Novartis AG Proliferative Vitreoretinopathy (PVR) Therapeutics Products Offered
11.1.5 Novartis AG Related Developments

12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Proliferative Vitreoretinopathy (PVR) Therapeutics Market Estimates and Projections by Region
12.1.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Forecast by Regions 2021-2026
12.1.2 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Forecast by Regions 2021-2026
12.2 North America Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size Forecast (2021-2026)
12.2.1 North America: Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Forecast (2021-2026)
12.2.2 North America: Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Forecast (2021-2026)
12.2.3 North America: Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size Forecast by Country (2021-2026)
12.3 Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size Forecast (2021-2026)
12.3.1 Europe: Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Forecast (2021-2026)
12.3.2 Europe: Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Forecast (2021-2026)
12.3.3 Europe: Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size Forecast by Region (2021-2026)
12.5 Latin America Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size Forecast (2021-2026)
12.5.1 Latin America: Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Forecast (2021-2026)
12.5.2 Latin America: Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Forecast (2021-2026)
12.5.3 Latin America: Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size Forecast by Country (2021-2026)

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Proliferative Vitreoretinopathy (PVR) Therapeutics Players (Opinion Leaders)

14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Proliferative Vitreoretinopathy (PVR) Therapeutics Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer

List of Tables
Table 1. Proliferative Vitreoretinopathy (PVR) Therapeutics Market Segments
Table 2. Ranking of Global Top Proliferative Vitreoretinopathy (PVR) Therapeutics Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size Growth Rate by Type 2020-2026 (K Pcs) & (US$ Million)
Table 4. Major Manufacturers of PRM-167
Table 5. Major Manufacturers of XOMA-089
Table 6. Major Manufacturers of Others
Table 7. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size Growth Rate by Application 2020-2026 (K Pcs)
Table 8. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size by Region (K Pcs) & (US$ Million): 2020 VS 2026
Table 9. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Regions 2015-2020 (K Pcs)
Table 10. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Regions (2015-2020)
Table 11. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Regions 2015-2020 (US$ Million)
Table 12. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Manufacturers (2015-2020) (K Pcs)
Table 13. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Share by Manufacturers (2015-2020)
Table 14. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 15. Global Proliferative Vitreoretinopathy (PVR) Therapeutics by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Proliferative Vitreoretinopathy (PVR) Therapeutics as of 2019)
Table 16. Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Manufacturers (2015-2020) (US$ Million)
Table 17. Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Share by Manufacturers (2015-2020)
Table 18. Key Manufacturers Proliferative Vitreoretinopathy (PVR) Therapeutics Price (2015-2020) (USD/Pcs)
Table 19. Proliferative Vitreoretinopathy (PVR) Therapeutics Manufacturers Manufacturing Base Distribution and Headquarters
Table 20. Manufacturers Proliferative Vitreoretinopathy (PVR) Therapeutics Product Type
Table 21. Date of International Manufacturers Enter into Proliferative Vitreoretinopathy (PVR) Therapeutics Market
Table 22. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 23. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Type (2015-2020) (K Pcs)
Table 24. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Share by Type (2015-2020)
Table 25. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Type (2015-2020) (US$ Million)
Table 26. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Share by Type (2015-2020)
Table 27. Proliferative Vitreoretinopathy (PVR) Therapeutics Average Selling Price (ASP) by Type 2015-2020 (USD/Pcs)
Table 28. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Application (2015-2020) (K Pcs)
Table 29. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Share by Application (2015-2020)
Table 30. North America Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Country (2015-2020) (K Pcs)
Table 31. North America Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Country (2015-2020)
Table 32. North America Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Country (2015-2020) (US$ Million)
Table 33. North America Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Market Share by Country (2015-2020)
Table 34. North America Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Type (2015-2020) (K Pcs)
Table 35. North America Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Type (2015-2020)
Table 36. North America Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Application (2015-2020) (K Pcs)
Table 37. North America Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Application (2015-2020)
Table 38. Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Country (2015-2020) (K Pcs)
Table 39. Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Country (2015-2020)
Table 40. Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Country (2015-2020) (US$ Million)
Table 41. Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Market Share by Country (2015-2020)
Table 42. Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Type (2015-2020) (K Pcs)
Table 43. Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Type (2015-2020)
Table 44. Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Application (2015-2020) (K Pcs)
Table 45. Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Application (2015-2020)
Table 46. Asia Pacific Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Region (2015-2020) (K Pcs)
Table 47. Asia Pacific Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Region (2015-2020)
Table 48. Asia Pacific Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Region (2015-2020) (US$ Million)
Table 49. Asia Pacific Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Market Share by Region (2015-2020)
Table 50. Asia Pacific Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Type (2015-2020) (K Pcs)
Table 51. Asia Pacific Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Type (2015-2020)
Table 52. Asia Pacific Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Application (2015-2020) (K Pcs)
Table 53. Asia Pacific Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Application (2015-2020)
Table 54. Latin America Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Country (2015-2020) (K Pcs)
Table 55. Latin America Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Country (2015-2020)
Table 56. Latin Americaa Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Country (2015-2020) (US$ Million)
Table 57. Latin America Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Market Share by Country (2015-2020)
Table 58. Latin America Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Type (2015-2020) (K Pcs)
Table 59. Latin America Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Type (2015-2020)
Table 60. Latin America Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Application (2015-2020) (K Pcs)
Table 61. Latin America Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Application (2015-2020)
Table 62. Middle East and Africa Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Country (2015-2020) (K Pcs)
Table 63. Middle East and Africa Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Country (2015-2020)
Table 64. Middle East and Africa Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue by Country (2015-2020) (US$ Million)
Table 65. Middle East and Africa Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Market Share by Country (2015-2020)
Table 66. Middle East and Africa Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Type (2015-2020) (K Pcs)
Table 67. Middle East and Africa Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Type (2015-2020)
Table 68. Middle East and Africa Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Application (2015-2020) (K Pcs)
Table 69. Middle East and Africa Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Application (2015-2020)
Table 70. Novartis AG Corporation Information
Table 71. Novartis AG Description and Major Businesses
Table 72. Novartis AG Proliferative Vitreoretinopathy (PVR) Therapeutics Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 73. Novartis AG Product
Table 74. Novartis AG Recent Development
Table 75. Promedior Inc Corporation Information
Table 76. Promedior Inc Description and Major Businesses
Table 77. Promedior Inc Proliferative Vitreoretinopathy (PVR) Therapeutics Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 78. Promedior Inc Product
Table 79. Promedior Inc Recent Development
Table 80. RXi Pharmaceuticals Corp Corporation Information
Table 81. RXi Pharmaceuticals Corp Description and Major Businesses
Table 82. RXi Pharmaceuticals Corp Proliferative Vitreoretinopathy (PVR) Therapeutics Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 83. RXi Pharmaceuticals Corp Product
Table 84. RXi Pharmaceuticals Corp Recent Development
Table 85. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Forecast by Regions (2021-2026) (K Pcs)
Table 86. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share Forecast by Regions (2021-2026)
Table 87. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 88. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Market Share Forecast by Regions (2021-2026)
Table 89. North America: Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Forecast by Country (2021-2026) (K Pcs)
Table 90. North America: Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Forecast by Country (2021-2026) (US$ Million)
Table 91. Europe: Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Forecast by Country (2021-2026) (K Pcs)
Table 92. Europe: Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Forecast by Country (2021-2026) (US$ Million)
Table 93. Asia Pacific: Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Forecast by Region (2021-2026) (K Pcs)
Table 94. Asia Pacific: Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Forecast by Region (2021-2026) (US$ Million)
Table 95. Latin America: Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Forecast by Country (2021-2026) (K Pcs)
Table 96. Latin America: Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Forecast by Country (2021-2026) (US$ Million)
Table 97. Middle East and Africa: Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Forecast by Country (2021-2026) (K Pcs)
Table 98. Middle East and Africa: Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Forecast by Country (2021-2026) (US$ Million)
Table 99. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 100. Key Challenges
Table 101. Market Risks
Table 102. Main Points Interviewed from Key Proliferative Vitreoretinopathy (PVR) Therapeutics Players
Table 103. Proliferative Vitreoretinopathy (PVR) Therapeutics Customers List
Table 104. Proliferative Vitreoretinopathy (PVR) Therapeutics Distributors List
Table 105. Research Programs/Design for This Report
Table 106. Key Data Information from Secondary Sources
Table 107. Key Data Information from Primary Sources
List of Figures
Figure 1. Proliferative Vitreoretinopathy (PVR) Therapeutics Product Picture
Figure 2. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Type in 2020 & 2026
Figure 3. PRM-167 Product Picture
Figure 4. XOMA-089 Product Picture
Figure 5. Others Product Picture
Figure 6. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Application in 2020 & 2026
Figure 7. Hospital
Figure 8. Clinic
Figure 9. ASCs
Figure 10. Others
Figure 11. Proliferative Vitreoretinopathy (PVR) Therapeutics Report Years Considered
Figure 12. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size 2015-2026 (US$ Million)
Figure 13. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales 2015-2026 (K Pcs)
Figure 14. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size Market Share by Region: 2020 Versus 2026
Figure 15. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Region (2015-2020)
Figure 16. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Region in 2019
Figure 17. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Market Share by Region (2015-2020)
Figure 18. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Market Share by Region in 2019
Figure 19. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Share by Manufacturer in 2019
Figure 20. The Top 10 and 5 Players Market Share by Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue in 2019
Figure 21. Proliferative Vitreoretinopathy (PVR) Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 22. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Type (2015-2020)
Figure 23. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Type in 2019
Figure 24. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Market Share by Type (2015-2020)
Figure 25. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Market Share by Type in 2019
Figure 26. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Market Share by Price Range (2015-2020)
Figure 27. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Application (2015-2020)
Figure 28. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Application in 2019
Figure 29. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Market Share by Application (2015-2020)
Figure 30. Global Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Market Share by Application in 2019
Figure 31. North America Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Growth Rate 2015-2020 (K Pcs)
Figure 32. North America Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Growth Rate 2015-2020 (US$ Million)
Figure 33. North America Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Country in 2019
Figure 34. North America Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Market Share by Country in 2019
Figure 35. U.S. Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 36. U.S. Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 37. Canada Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 38. Canada Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 39. North America Proliferative Vitreoretinopathy (PVR) Therapeutics Market Share by Type in 2019
Figure 40. North America Proliferative Vitreoretinopathy (PVR) Therapeutics Market Share by Application in 2019
Figure 41. Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Growth Rate 2015-2020 (K Pcs)
Figure 42. Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Growth Rate 2015-2020 (US$ Million)
Figure 43. Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Country in 2019
Figure 44. Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Market Share by Country in 2019
Figure 45. Germany Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 46. Germany Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 47. France Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 48. France Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 49. U.K. Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 50. U.K. Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 51. Italy Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 52. Italy Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 53. Russia Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 54. Russia Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 55. Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Market Share by Type in 2019
Figure 56. Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Market Share by Application in 2019
Figure 57. Asia Pacific Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Growth Rate 2015-2020 (K Pcs)
Figure 58. Asia Pacific Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Growth Rate 2015-2020 (US$ Million)
Figure 59. Asia Pacific Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Region in 2019
Figure 60. Asia Pacific Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Market Share by Region in 2019
Figure 61. China Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 62. China Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 63. Japan Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 64. Japan Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 65. South Korea Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 66. South Korea Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 67. India Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 68. India Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 69. Australia Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 70. Australia Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 71. Taiwan Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 72. Taiwan Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 73. Indonesia Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 74. Indonesia Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 75. Thailand Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 76. Thailand Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 77. Malaysia Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 78. Malaysia Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 79. Philippines Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 80. Philippines Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 81. Vietnam Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 82. Vietnam Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 83. Asia Pacific Proliferative Vitreoretinopathy (PVR) Therapeutics Market Share by Type in 2019
Figure 84. Asia Pacific Proliferative Vitreoretinopathy (PVR) Therapeutics Market Share by Application in 2019
Figure 85. Latin America Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Growth Rate 2015-2020 (K Pcs)
Figure 86. Latin America Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Growth Rate 2015-2020 (US$ Million)
Figure 87. Latin America Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Country in 2019
Figure 88. Latin America Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Market Share by Country in 2019
Figure 89. Mexico Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 90. Mexico Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 91. Brazil Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 92. Brazil Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 93. Argentina Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 94. Argentina Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 95. Latin America Proliferative Vitreoretinopathy (PVR) Therapeutics Market Share by Type in 2019
Figure 96. Latin America Proliferative Vitreoretinopathy (PVR) Therapeutics Market Share by Application in 2019
Figure 97. Middle East and Africa Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Growth Rate 2015-2020 (K Pcs)
Figure 98. Middle East and Africa Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Growth Rate 2015-2020 (US$ Million)
Figure 99. Middle East and Africa Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Market Share by Country in 2019
Figure 100. Middle East and Africa Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Market Share by Country in 2019
Figure 101. Turkey Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 102. Turkey Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 103. Saudi Arabia Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 104. Saudi Arabia Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 105. U.A.E Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 106. U.A.E Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 107. Middle East and Africa Proliferative Vitreoretinopathy (PVR) Therapeutics Market Share by Type in 2019
Figure 108. Middle East and Africa Proliferative Vitreoretinopathy (PVR) Therapeutics Market Share by Application in 2019
Figure 109. North America Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 110. North America Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 111. Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 112. Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 113. Asia Pacific Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 114. Asia Pacific Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 115. Latin America Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 116. Latin America Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 117. Middle East and Africa Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 118. Middle East and Africa Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 119. Porter's Five Forces Analysis
Figure 120. Channels of Distribution
Figure 121. Distributors Profiles
Figure 122. Bottom-up and Top-down Approaches for This Report
Figure 123. Data Triangulation
Figure 124. Key Executives Interviewed

---